多瑞吉治疗42例中、重度晚期癌痛

目的　观察多瑞吉 (芬太尼贴剂 )治疗晚期癌痛患者的镇痛效果和不良反应。方法　 4 2例晚期癌痛患者 ,治疗前均为中、重度疼痛 ,使用多瑞吉镇痛治疗 ,每 2 4小时评定疗效一次 ,至少观察 15天。结果　全组完全缓解 5例 (11.9% ) ,明显缓解 31例 (73.8% ) ,总有效率为 85 .7%。不良反应主要为便秘、恶心呕吐、皮肤瘙痒及嗜睡等 ,发生率低。结论　多瑞吉治疗中、重度癌痛 ,镇痛效果好 ,不良反应小 ,值得临床进一步推广应用。

Durogesic in 42 patients with moderate or severe cancer pain

Objective To observe the efficacy and adverse reactions of Durogesic (transdermal fentanyl) in patients with cancer pain. Methods 42 patients with moderate or severe cancer pain were treated by Durogesic. The pain intensity and curative effects were assessed every 24 hours. Results The complete and marked remission rate was 11.9% and 73.8% respectively. The overall effective rate was 85.7% . The chief adverse reactions were constipation,nausea,vomiting, and itch of skin,sleepy and so on. The rate of adverse reactions was less. Most of the adverse reactions subsided along with the long time use of Durogesic. Conclusion Durogesic is significantly effective in treatment of moderate or severe cancer pain and the adverse reactions are mild. Furthermore clinical application is worthwhile.